Ocumension Therapeutics (SZSC:1477) - Stock Price, News & Analysis

1477 Stock Overview

Operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. More details

1477 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 59.4% below our estimate of its fair value

Earnings are forecast to grow 101.88% per year

Earnings have grown 50.6% per year over the past 5 years

Analysts in good agreement that stock price will rise by 91.2%

Risk Analysis

Shareholders have been diluted in the past year

Ocumension Therapeutics Competitors

YiChang HEC ChangJiang Pharmaceutical

SEHK:1558

HK$8.2b

China Shineway Pharmaceutical Group

SEHK:2877

HK$6.1b

Tong Ren Tang Technologies

SEHK:1666

HK$6.4b

Consun Pharmaceutical Group

SEHK:1681

HK$6.8b

Price History & Performance

Summary of all time highs, changes and price drops for Ocumension Therapeutics
Historical stock prices
Current Share Price	HK$5.19
52 Week High	HK$7.54
52 Week Low	HK$4.13
Beta	0.80
11 Month Change	-8.95%
3 Month Change	-2.99%
1 Year Change	-28.02%
33 Year Change	-71.07%
5 Year Change	n/a
Change since IPO	-77.29%

Recent updates

Shareholder Returns

	1477	HK Pharmaceuticals	HK Market
7D	1.8%	0.07%	-0.6%
1Y	-28.0%	-10.2%	9.6%

Return vs Industry: 1477 underperformed the Hong Kong Pharmaceuticals industry which returned -10.2% over the past year.

Return vs Market: 1477 underperformed the Hong Kong Market which returned 9.6% over the past year.

Price Volatility

Is 1477's price volatile compared to industry and market?
1477 volatility
1477 Average Weekly Movement	8.7%
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	19.2%
10% least volatile stocks in HK Market	4.3%

Stable Share Price: 1477 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 1477's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2017	477	Victor Liu	www.ocumension.com

Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, blepharitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, acute glaucoma, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis.

Ocumension Therapeutics Fundamentals Summary

How do Ocumension Therapeutics's earnings and revenue compare to its market cap?
1477 fundamental statistics
Market cap	HK$4.24b
Earnings (TTM)	-HK$346.72m
Revenue (TTM)	HK$333.37m

12.7x

P/S Ratio

-12.2x

P/E Ratio

Is 1477 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1477 income statement (TTM)
Revenue	CN¥310.29m
Cost of Revenue	CN¥129.44m
Gross Profit	CN¥180.86m
Other Expenses	CN¥503.58m
Earnings	-CN¥322.73m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.39
Gross Margin	58.29%
Net Profit Margin	-104.01%
Debt/Equity Ratio	0%

How did 1477 perform over the long term?

See historical performance and comparison

1477 Stock Overview

Rewards

Risk Analysis

Ocumension Therapeutics Competitors

SEHK:1558

HK$8.2b

SEHK:2877

HK$6.1b

SEHK:1666

HK$6.4b

SEHK:1681

HK$6.8b

Price History & Performance

Recent News & Updates

Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director

New minor risk - Shareholder dilution

Ocumension Therapeutics Announces New Drug Application of OT-502 Accepted by the National Medical Products Administration

Ocumension Therapeutics Announces New Drug Application of OT-1001 Approved by the National Medical Products Administration

New minor risk - Profitability

First half 2024 earnings released: CN¥0.23 loss per share (vs CN¥0.32 loss in 1H 2023)

Recent updates

Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director

New minor risk - Shareholder dilution

Ocumension Therapeutics Announces New Drug Application of OT-502 Accepted by the National Medical Products Administration

Ocumension Therapeutics Announces New Drug Application of OT-1001 Approved by the National Medical Products Administration

New minor risk - Profitability

First half 2024 earnings released: CN¥0.23 loss per share (vs CN¥0.32 loss in 1H 2023)

Ocumension Therapeutics to Report First Half, 2024 Results on Aug 12, 2024

Ocumension Therapeutics Announces Biologic License Application for OT-702 Accepted by the National Medical Products Administration

Ocumension Therapeutics, Annual General Meeting, Jun 20, 2024

Full year 2023 earnings released: CN¥0.58 loss per share (vs CN¥0.64 loss in FY 2022)

Full year 2023 earnings released: CN¥0.59 loss per share (vs CN¥0.64 loss in FY 2022)

Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202

Ocumension Therapeutics to Report Fiscal Year 2023 Results on Mar 21, 2024

Ocumension Therapeutics (SEHK:1477) commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023.

Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China

Ocumension Therapeutics Completes Patient Enrollment in the Phase II Clinical Trial of OT-202 in China

Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023

New minor risk - Profitability

First half 2023 earnings released: CN¥0.32 loss per share (vs CN¥0.31 loss in 1H 2022)

Ocumension Therapeutics to Report First Half, 2023 Results on Aug 24, 2023

Ocumension Therapeutics Announces Clinical Trial Authorization for Initiating A Phase III Clinical Trial of Ot-101-S

Forecast to breakeven in 2025

Ocumension Therapeutics Completes Patient Enrollment in Globalmulti-Center Phase III Clinical Trial of OT-101

Full year 2022 earnings released: CN¥0.64 loss per share (vs CN¥0.43 loss in FY 2021)

Ocumension Therapeutics Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended December 31, 2022

No longer forecast to breakeven

Ocumension Therapeutics Provides Update on Phase I Clinical Trial of Ot-202

Ocumension Therapeutics Announces Patient Enrollment Complete in the Phase III Clinical Trial of OT-101 in China

Now 22% undervalued

Now 22% undervalued after recent price drop

Less than half of directors are independent

First half 2022 earnings released: CN¥0.31 loss per share (vs CN¥0.12 loss in 1H 2021)

Ocumension Therapeutics to Report First Half, 2022 Results on Aug 26, 2022

Board Member recently sold HK$246k worth of stock

Now 24% undervalued

Ocumension Therapeutics Receives Approval from the National Medical Products Administration for Yutio Chronic Non-Infectious Uveitis

EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ(R) for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Ocumension Therapeutics Announces Executive Changes

Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-703 in China

Ocumension Therapeutics Receives Approval from the National Medical Products Administration for its IND Application to Begin the Phase Iii Clinical Study for Fluocinolone Acetonide Intravitreal Implant

Less than half of directors are independent

Ocumension Therapeutics Appoints Mr. Zhenyu Zhang as Independent Non-Executive Director, the Chairman of the Remuneration Committee and a Member of the Nomination Committee and Audit Committee

Ocumension Therapeutics Announces Demise of Lianming HE, Independent Non-Executive Director, Chairman of the Remuneration Committee and Member of the Audit Committee and Nomination Committee

Forecast to breakeven in 2024

Full year 2021 earnings released: CN¥0.43 loss per share (vs CN¥7.49 loss in FY 2020)

Ocumension Therapeutics Voluntary Announcement primary Clinical Endpoint Achieved in the Phase III clinical Trial of OT-1001

Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China

Ocumension Therapeutics Announces First Patient Enrolled in the Clinical Trial of self-Developed Class I New Drug OT-202 in China

First half 2021 earnings released: CN¥0.12 loss per share (vs CN¥27.36 loss in 1H 2020)

Ocumension Therapeutics Receives CDE Approval for Commencement of a Phase III Clinical Trial OT-502 (DEXYCU®) in China

First half 2021 earnings released: CN¥0.12 loss per share (vs CN¥27.36 loss in 1H 2020)

Ocumension Therapeutics MHRA Approval Received for Phase III Clinical Trial of OT-101 in the United Kingdom

Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-101

Ocumension Therapeutics Announces Clinical Trial Authorization for Initiatinga Phase III Clinical Trial of OT-101 Accepted in United Kingdom

Ocumension Therapeutics Announces Investigational New Drug Application for Initiating A Multi-Regional Phase Iii Clinical Trial in the People's Republic of China for OT-101

Non-Executive Director has left the company

Ocumension Therapeutics Announces Board Changes

Ocumension Therapeutics, Annual General Meeting, Jun 29, 2021

Shareholder Returns